Literature DB >> 29395335

The atypical chemokine receptor 2 limits renal inflammation and fibrosis in murine progressive immune complex glomerulonephritis.

Andrei Bideak1, Alexander Blaut1, John M Hoppe1, Martin B Müller1, Giuseppina Federico2, Nuru Eltrich1, Hermann-Josef Gröne2, Massimo Locati3, Volker Vielhauer4.   

Abstract

The atypical chemokine receptor 2 (ACKR2), also named D6, regulates local levels of inflammatory chemokines by internalization and degradation. To explore potential anti-inflammatory functions of ACKR2 in glomerulonephritis, we induced autologous nephrotoxic nephritis in C57/BL6 wild-type and Ackr2-deficient mice. Renal ACKR2 expression increased and localized to interstitial lymphatic endothelium during nephritis. At two weeks Ackr2-/-mice developed increased albuminuria and urea levels compared to wild-type mice. Histological analysis revealed increased structural damage in the glomerular and tubulointerstitial compartments within Ackr2-/- kidneys. This correlated with excessive renal leukocyte infiltration of CD4+ T cells and mononuclear phagocytes with increased numbers in the tubulointerstitium but not glomeruli in knockout mice. Expression of inflammatory mediators and especially markers of fibrotic tissue remodeling were increased along with higher levels of ACKR2 inflammatory chemokine ligands like CCL2 in nephritic Ackr2-/- kidneys. In vitro, Ackr2 deficiency in TNF-stimulated tubulointerstitial tissue but not glomeruli increased chemokine levels. These results are in line with ACKR2 expression in interstitial lymphatic endothelial cells, which also assures efflux of activated leukocytes into regional lymph nodes. Consistently, nephritic Ackr2-/- mice showed reduced adaptive cellular immune responses indicated by decreased regional T-cell activation. However, this did not prevent aggravated injury in the kidneys of Ackr2-/- mice with nephrotoxic nephritis due to simultaneously increased tubulointerstitial chemokine levels, leukocyte infiltration and fibrosis. Thus, ACKR2 is important in limiting renal inflammation and fibrotic remodeling in progressive nephrotoxic nephritis. Hence, ACKR2 may be a potential target for therapeutic interventions in immune complex glomerulonephritis.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chemokine; fibrosis; glomerulonephritis; inflammation

Mesh:

Substances:

Year:  2018        PMID: 29395335     DOI: 10.1016/j.kint.2017.11.013

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

1.  A pH-Responsive System Based on Fluorescence Enhanced Gold Nanoparticles for Renal Targeting Drug Delivery and Fibrosis Therapy.

Authors:  Xuandi Lai; Xinran Geng; Lishan Tan; Jianqiang Hu; Shubin Wang
Journal:  Int J Nanomedicine       Date:  2020-08-06

2.  Overexpressed angiotensin-converting enzyme in neutrophils suppresses glomerular damage in crescentic glomerulonephritis.

Authors:  Suguru Saito; Narihito Tatsumoto; Duo-Yao Cao; Nobuyuki Nosaka; Hiroshi Nishi; Daniel N Leal; Ellen Bernstein; Kenichi Shimada; Moshe Arditi; Kenneth E Bernstein; Michifumi Yamashita
Journal:  Am J Physiol Renal Physiol       Date:  2022-08-18

Review 3.  The Role of Atypical Chemokine Receptor D6 (ACKR2) in Physiological and Pathological Conditions; Friend, Foe, or Both?

Authors:  Arezoo Gowhari Shabgah; Farhad Jadidi-Niaragh; Hamed Mohammadi; Farnoosh Ebrahimzadeh; Maziar Oveisee; Abbas Jahanara; Jamshid Gholizadeh Navashenaq
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

Review 4.  G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis.

Authors:  Emiel P C van der Vorst; Linsey J F Peters; Madeleine Müller; Selin Gencer; Yi Yan; Christian Weber; Yvonne Döring
Journal:  Front Pharmacol       Date:  2019-05-22       Impact factor: 5.810

Review 5.  The kidney, COVID-19, and the chemokine network: an intriguing trio.

Authors:  Gianluigi Taverna; Simona Di Francesco; Elena Monica Borroni; Daniel Yiu; Elena Toniato; Samantha Milanesi; Maurizio Chiriva-Internati; Robert S Bresalier; Matteo Zanoni; Paolo Vota; Davide Maffei; Matteo Justich; Fabio Grizzi
Journal:  Int Urol Nephrol       Date:  2020-07-27       Impact factor: 2.370

Review 6.  Koebner phenomenon leading to the formation of new psoriatic lesions: evidences and mechanisms.

Authors:  Yong-Zhi Ji; Shi-Rui Liu
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

7.  CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6.

Authors:  Andy Chevigné; Bassam Janji; Max Meyrath; Nathan Reynders; Giulia D'Uonnolo; Tomasz Uchański; Malina Xiao; Guy Berchem; Markus Ollert; Yong-Jun Kwon; Muhammad Zaeem Noman; Martyna Szpakowska
Journal:  Cancers (Basel)       Date:  2021-03-02       Impact factor: 6.639

8.  A Meta-Analysis of Human Transcriptomics Data in the Context of Peritoneal Dialysis Identifies Novel Receptor-Ligand Interactions as Potential Therapeutic Targets.

Authors:  Michail Evgeniou; Juan Manuel Sacnun; Klaus Kratochwill; Paul Perco
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

9.  A novel insight into differential expression profiles of sporadic cerebral cavernous malformation patients with different symptoms.

Authors:  Hilal Eren Gozel; Kıvanç Kök; Fatma Ozlen; Cihan Isler; Sadrettin Pence
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

Review 10.  Covid-19 and kidney injury: Pathophysiology and molecular mechanisms.

Authors:  Elham Ahmadian; Seyed Mahdi Hosseiniyan Khatibi; Saiedeh Razi Soofiyani; Sima Abediazar; Mohammadali M Shoja; Mohammadreza Ardalan; Sepideh Zununi Vahed
Journal:  Rev Med Virol       Date:  2020-10-06       Impact factor: 11.043

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.